Back to results
US 2017/0283481 A1Published application
Engineered Invariant Natural Killer T (iNKT) Cells and Methods of Making and Using Thereof
AssigneeThe Regents of the University of California
InventorsLili Yang, Drake J. Smith
Life of this patent
Estimating the term…
Abstract
Disclosed are invariant natural killer T (iNKT) cells engineered using hematopoietic stem and progenitor cells (HSPCs) and methods of making and using thereof. Specifically, the engineered cells iNKT are genetically modified to contain at least one exogenous invariant natural killer T cell receptor (iNKT TCR) nucleic acid molecule. Further disclosed are iNKT TCR nucleotide sequences and codon optimized sequences for expression.
Claims20
An engineered cell which is a cell genetically modified to contain at least one exogenous invariant natural killer T cell receptor (iNKT TCR) nucleic acid molecule.
Dependencies are inferred from the claim text.